ArticleFrontiers in medicine2026
Horizon scanning at EMA: preparing for the medicines of the future.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This article provides insights into the European Medicines Agency's approach to horizon scanning as a foresight tool to support early identification, analysis and preparedness for emerging trends, technologies and challenges relevant to medicines development and authorization. Emerging topics are identified through a continuous scanning of several sources of information, including key trends identified by leading institutions such as the World Health Organization, the European Commission Joint Research Centre, and the European Innovation Council. This perspective sets out the scope, impact and outputs of horizon scanning within the European medicines regulatory network, which include topic-specific reports, collaborative workshops and webinars, and contributions to regulatory policy, strategic planning, capacity building and research prioritization. It also emphasizes the European medicines regulatory network's commitment to collaboration and knowledge sharing across European and international organizations. Through these efforts, horizon scanning supports regulatory preparedness and resilience of the European medicines regulatory system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.